Form 4: Travere Therapeutics Officer Jula Inrig Sells Shares Under 10b5-1 Plan

Jula Inrig, Chief Medical Officer of Travere Therapeutics, sold 684 shares of common stock at $12.98 per share on September 10, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On September 10, 2024, Jula Inrig, the Chief Medical Officer of Travere Therapeutics, sold 684 shares of the company's common stock.
• The sale was executed at a price of $12.98 per share.
• This transaction was conducted under a pre-existing written trading plan that complies with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
• The plan was adopted on March 15, 2024.
• The sale included shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that vested on September 5, 2024.
• Following the transaction, Inrig directly owns 61,949 shares of Travere Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine transaction under a pre-existing trading plan. There is no indication of positive or negative implications for the company's performance.

Industry Context

This is a routine disclosure of an insider stock sale. Insider sales can sometimes be viewed negatively by the market, but the existence of a 10b5-1 plan suggests the sale was pre-planned and not based on any inside information.

Stakeholder Impact

• The stock sale by a key officer could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates